Pharmafile Logo
Pharmafocus logo
Advanced Search

OMass Therapeutics raises $100 million to progress immunology and rare diseases drug pipeline

April 28, 2022
Business Services

OMass Therapeutics have announced the $100 million (£75.5 million) Series B financing to progress its drug pipeline in immunology and …

News
fdaoutsideweb

NOCIRA announces breakthrough device designation by FDA for migraine treatment

April 28, 2022
Business Services

NOCIRA is the first company to announce the FDA’s Breakthrough Device designation for the treatment of migraine attacks in both …

News

Quell Therapeutics and Cellistic collaborate to develop T-regulatory cell therapy platform

April 27, 2022
Research and Development

Quell Therapeutics and Cellistic have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform. …

News

Almost 200 cases of unexplained acute hepatitis in children

April 27, 2022

Around 190 unexplained cases of severe hepatitis have been found in children around the world, as scientists urgently investigate what …

News

Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis

April 27, 2022
Research and Development

Orexo has announced that their partner, Gesynta Pharma has been granted Orphan Drug Designation by the FDA, for OX-MPI (GS248), …

News

Enhertu granted FDA Breakthrough Therapy Designation

April 27, 2022
Research and Development

AstraZeneca’s Enhertu® (fam-trastuzumab deruxtecan-nxki) has been granted breakthrough therapy designation in the US for adult patients with HER2-low metastatic breast …

News

Beijing enforces mass COVID-19 testing and closes neighbourhoods

April 26, 2022
Medical Communications

Beijing is enforcing mass testing and closing down access to neighbourhoods as it seeks to contain a new COVID-19 outbreak. …

News

UK study finds raising frequency of COPD flare ups increases risk of death

April 26, 2022
Manufacturing and Production

The EXACOS UK study in Chronic Obstructive Pulmonary Disease (COPD), funded by AstraZeneca, has shown that an increasing frequency of …

News

FDA approves first COVID-19 treatment for young children

April 26, 2022
Manufacturing and Production

The FDA has expanded the approval of the COVID-19 treatment, Veklury (remdesivir), to include pediatric patients 28 days of age …

News

Mundipharma and Cidara Therapeutics report positive Phase III results into candidemia treatment

April 26, 2022
Medical Communications

Mundipharma and Cidara Therapeutics have presented data from the Phase III ReSTORE trial of rezafungin, in the treatment of candidemia …

News

New data for Shionogi’s COVID-19 antiviral show rapid virus clearance

April 25, 2022
Sales and Marketing

Shionogi has announced new results from two late-breaking presentations of S-217622. This is an investigational 3CL protease inhibitor that was …

News

National shortage of HRT medication due to high demand

April 25, 2022
Sales and Marketing

The national shortage of HRT products could have an impact on some women, who may not be able to sleep …

News

EMA recommend new treatment option for severe postpartum haemorrhage

April 25, 2022
Sales and Marketing

Novo Nordisk has announced that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …

News

Ukraine: crisis for people with chronic diseases

April 25, 2022
Sales and Marketing

Preliminary results from an ongoing nationwide health needs assessment, conducted by WHO in partnership with Premise, indicate that one in …

News

Vivesto signs agreement with CRO to evaluate anti-cancer drug formulations

April 22, 2022
Medical Communications

Vivesto AB, an oncology-focused pharmaceutical company, has announced that it is advancing research into its proprietary drug delivery formulations, and …

News

Orasis Pharmaceuticals announces positive Phase III results of eye drop candidate

April 22, 2022
Medical Communications

Orasis Pharmaceuticals has announced that the Phase III NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of …

News

FDA approves Phase III Acute Respiratory Distress Syndrome (ARDS) Trial

April 22, 2022
Medical Communications

The FDA has approved Direct Biologics to proceed with its Phase III clinical trial into the treatment of Acute Respiratory …

News

WHO “strongly recommends” Paxlovid, calls for wide distribution from Pfizer

April 22, 2022
Medical Communications

WHO has endorsed the use of Pfizer’s oral antiviral treatment for high-risk patients with mild COVID-19, following an analysis of …

News

NIHR-supported trial reveals vaccine boosters maintain immunity three months on

April 21, 2022
Business Services

Latest results form the UK’s COV-BOOST study, led by University Hospital Southampton, have shown prolonged immune responses following third doses …

News

FDA’s Cancer Advisory Committee to evaluate safety of P13K inhibitors

April 21, 2022
Business Services

The FDA’s Oncologic Drugs Advisory Committee is holding a meeting today to discuss safety findings across the entire class of …

News
The Gateway to Local Adoption Series

Latest content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026

Sandoz’ Ondibta receives European Commission approval for diabetes

January 26, 2026

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026